# Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial

*PRI Rank #11 · Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026/rank-11*

| Field | Value |
| --- | --- |
| Rank | #11 |
| 18m citations | 69 |
| Journal | Nature Medicine |
| Year | 2024 |
| DOI | 10.1038/s41591-023-02786-7 |
| Corresponding authors | Shuqun Cheng |
| Institution | Eastern Hepatobiliary Surgery Hospital, China |

**Ranking page:** [Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026](https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026)

**Paper link:** [10.1038/s41591-023-02786-7](https://doi.org/10.1038/s41591-023-02786-7)

## Topics

sintilimab · Hepatocellular carcinoma · adjuvant therapy · resected hepatocellular carcinoma · High-risk HCC · PD-1/PD-L1 inhibitor · Immune checkpoint inhibitor therapy · Randomized controlled trial · Phase 2 clinical trial · Hepatectomy · Recurrence-free survival · Overall survival · postoperative adjuvant immunotherapy · Tumor recurrence · Hepatocellular carcinoma

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```